McElwain T J, Hedley D W, Gordon M Y, Jarman M, Millar J L, Pritchard J
Exp Hematol. 1979;7 Suppl 5:360-71.
Autologous non-cryopreserved bone marrow infused 8 hours after an intravenous injection of melphalan, 140 mg/m2, accelerates bone marrow recovery. This effect is most noticeable in the recovery of peripheral blood granulocytes. Twenty patients with disseminated malignant melanoma were treated with this regimen: there were 12 responses, two of them complete but the toxicity of the treatment was not sufficient to justify using this method of treatment routinely since survival was little influenced by treatment (4-11 months). In 8 patients with disseminated neuroblastoma, high dose melphalan/autograft was used in a program of combined modality treatment. Three of the patients are disease free at 16, 11 and 6 months and in one the disease is 'static', not having grown for 13 months. The treatment for this tumour deserves further exploration, and perhaps similar treatment ought to be explored for other tumours.
在静脉注射140mg/m²马法兰8小时后输注自体非冷冻保存的骨髓，可加速骨髓恢复。这种效果在外周血粒细胞恢复方面最为明显。20例播散性恶性黑色素瘤患者接受了该治疗方案：有12例出现反应，其中2例完全缓解，但由于生存受治疗影响不大（4 - 11个月），该治疗的毒性不足以证明常规使用这种治疗方法是合理的。在8例播散性神经母细胞瘤患者中，高剂量马法兰/自体移植被用于综合治疗方案。其中3例患者分别在16个月、11个月和6个月时无疾病进展，还有1例患者病情“稳定”，已13个月未进展。对该肿瘤的治疗值得进一步探索，或许对其他肿瘤也应探索类似的治疗方法。
